

# Adult Mesenchymal Stem Cells and Cell Surface Characterization - A Systematic Review of the Literature

P. Mafi<sup>1</sup>, S. Hindocha<sup>\*2,3</sup>, R. Mafi<sup>1</sup>, M. Griffin<sup>2</sup> and W.S. Khan<sup>4</sup>

<sup>1</sup>The Hull York Medical School, Heslington, York YO10 5DD, UK

<sup>2</sup>Manchester Interdisciplinary Biocentre, University of Manchester, 131 Princess Street, M17DN, UK

<sup>3</sup>Department of Plastic Surgery, Whiston General Hospital, Liverpool, L355DR, UK

<sup>4</sup>University College London Institute of Orthopaedics and Musculoskeletal Sciences, Royal National Orthopaedic Hospital, Stanmore, Middlesex, HA7 4LP, UK

**Abstract:** Human adult mesenchymal stem cells (MSCs) were first identified by Friedenstein *et al.* when observing a group of cells that developed into fibroblastic colony forming cells (CFU-F). Ever since, the therapeutic uses and clinical applications of these cells have increased research and interest in this field. MSCs have the potential to be used in tissue engineering, gene therapy, transplants and tissue injuries. However, identifying these cells can be a challenge. Moreover, there are no articles bringing together and summarizing the cell surface markers of MSCs in adults. The purpose of this study is to summarize all the available information about the cell surface characterization of adult human MSCs by identifying and evaluating all the published literature in this field. We have found that the most commonly reported positive markers are CD105, CD90, CD44, CD73, CD29, CD13, CD34, CD146, CD106, CD54 and CD166. The most frequently reported negative markers are CD34, CD14, CD45, CD11b, CD49d, CD106, CD10 and CD31. A number of other cell surface markers including STRO-1, SH2, SH3, SH4, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-I, DP, EMA, DQ (MHC Class II), CD105, Oct 4, Oct 4A, Nanog, Sox-2, TERT, Stat-3, fibroblast surface antigen, smooth muscle alpha-actin, vimentin, integrin subunits alpha4, alpha5, beta1, integrins alphavbeta3 and alphavbeta5 and ICAM-1 have also been reported. Nevertheless, there is great discrepancy and inconsistency concerning the information available on the cell surface profile of adult MSCs and we suggest that further research is needed in this field to overcome the problem.

**Keywords:** Bone marrow derived multipotent progenitor cells; cell surface profile; mesenchymal stem cells; surface markers.

## INTRODUCTION

About 130 years ago, the German pathologist Cohnheim proposed the existence of non-hematopoietic stem cells in the bone marrow. He suggested that these cells could contribute to wound healing as they can be a source of fibroblasts [1]. Later, Friedenstein *et al.* identified human adult mesenchymal stem cells when observing a group of cells that developed into fibroblastic colony forming cells (CFU-F) [2]. Friedenstein provided strong evidence for the self-renewal potential of stem cells by demonstrating their ability to regenerate heterotropic bone tissue. These findings have been confirmed and expanded by many further laboratory studies which have shown that the cells isolated by Friedenstein can also be found in human bone marrow and could differentiate into a range of different mesenchymal lineage cells including chondrocytes, adipocytes, myoblasts and osteoblasts [1, 3-6].

Simmons *et al.* found that stromal cells supporting hematopoiesis were different to hematopoietic cells by showing that sexmismatched HLA-identical cells from patients solely expressed the host genotype [7]. This again supports Friedenstein's findings showing hematopoietic

stem cells were physically different from transplanted sexmismatched cells capable of heterotropic osseous tissue formation [8]. Now that these cells are found to be different, research is being done to identify whether there exist specific cell surface antigens to identify phenotypic differences between mesenchymal and hematopoietic stem cells. Even though many mesenchymal stem cell surface antigens have been cultured, there have been very few *in vivo* phenotypic characterization of MSCs [9]. Bianco *et al.* conducted one of the first studies with the intention of characterizing MSC-like cells both histologically and phenotypically. Interestingly, it has been shown that a wide range of non-hematopoietic stem cells exist in the bone marrow and that MSC are merely a subset of this population. These include "multipotent adult progenitor cells" (MAPCs), "endothelial progenitor cells" (EPCs), "marrow-isolated adult multilineage inducible cells" (MIAMI), "very small embryonic-like stem cells" (VSELs) [9-13].

Crisan *et al.* has found that multipotent mesenchymal stem cells exist in many different human organs [14]. To support this fact, it has been shown that MSCs are not confined to bone marrow and can also be found in placenta, dental pulp, tendons, skeletal muscle, fat, umbilical cord blood and amniotic fluid [14-22]. Despite the common belief that mesenchymal stem cells are derived from the embryonic mesoderm, a recent study by Takashima and colleagues showed that the earliest lineage of MSC-like cells are

\*Address correspondence to this author at the Manchester Interdisciplinary Biocentre, University of Manchester, 131 Princess Street, M17DN, UK; Tel: 01244366265; Fax: 01244366277; E-mail: hindocha2001@yahoo.com

developed, at least in part, from Sox1(+) neuroepithelium through a neural crest intermediate stage rather than from mesoderm [23]. These cells have been shown to be replaced by MSCs in later development. Nagoshi and colleagues have recently demonstrated that neural crest-derived cells migrate through the bloodstream to the bone marrow [24]. These cells are present in the bone marrow and can develop into myofibroblasts, glial cells and neurons. Further research is needed to assess whether there is a link between cells identified by Friedenstein and those identified by Takashima and colleagues [25].

Various studies have demonstrated the potential use of MSCs in gene therapy, transplants due to their special immunogenic properties and tissue injuries. Current research aims at characterizing, expanding and identifying ways to keep MSCs in the undifferentiated state, with the intention of transplanting them back to repair bone and cartilage [26-31]. Phinney and Prockop argue that mesenchymal stem cells could form the basis for a highly potent "natural system of tissue repair" [32]. Many further experimental models of tissue injuries have demonstrated the therapeutic properties of MSCs upon exogenous administration [33-37]. Prockop pointed out to an interesting fact that in the greater proportion of studies, there has been no correlation between the therapeutic effectiveness and the engraftment efficacy [38]. Furthermore, his findings suggest that the ability to repair was secondary to secretion of soluble factors by MSCs that changed the environment of the tissue [38]. Adult human mesenchymal stem cells have also been shown to have non-immunogenic surface antigens, due to possessing major histocompatibility complex class I protein (MHC I) instead of MHC II [39]. This is undoubtedly a valuable characteristic of adult MSCs which could make it possible to transplant them into an allogenic host without any need for immunosuppression [25]. Many attempts have also been done in order to apply MSCs in gene therapy. This includes their application in Lobstein disease in humans upon systemic administration [40, 41]. Nevertheless, extensive research needs to be done in this field, as our knowledge about their potential use in gene therapy is still very primitive. Also, not much is known about the phenotypic character, developmental origin and their contribution to organogenesis; an assay to demonstrate their self-renewability *in vivo* is still missing [25].

The therapeutic uses and clinical applications of MSCs have increased research and interest in identifying these cells. Despite 1% of the bone marrow population consisting of hematopoietic cells only 1/10000 to 1/100000 of the bone marrow nuclear cells are MSCs [42, 43]. Moreover, there is not adequate information about the cell surface markers of adult mesenchymal stem cells and how they can be identified. Therefore, correct identification of these cells can be a challenge. There are no articles bringing together and summarizing the cell surface markers of mesenchymal stem cells in adults. The purpose of this study is to summarize all the available information about the cell surface characterization of adult human mesenchymal stem cells by identifying and evaluating all the published literature in this field. The studies reporting mesenchymal stem cell surface markers were searched predominantly using Medline, CINAHL (EBSCO), ZETOC, PubMed, EMBASE and

AMED. This systematic review is intended to provide a good basis for identification and selection of adult human mesenchymal stem cells.

## MATERIALS AND METHOD

The studies referencing the cell surface markers of adult mesenchymal cells were searched using the electronic databases Medline, CINAHL (EBSCO), ZETOC, PubMed, EMBASE, AMED, PREMEDLINE In-Process & Non-Indexed Citations (OvidSP), ASSIA (CSA Illumina), Conference Proceedings Citation Index: Science (ISI) on Web of Knowledge, PsycINFO (OvidSP), Science Citation Index (ISI) on Web of Knowledge, Social Sciences Citation Index (ISI) on Web of Knowledge and Cochrane Library (Wiley). The following keywords were used to cite relevant articles: adult mesenchymal stem cells, bone marrow-derived multipotent progenitor cells, cell surface profile, MSCs, surface markers. The inclusion criteria were based on 1) characterization of cell surface markers of mesenchymal stem cells 2) identifying mesenchymal stem cells in adults. Studies were excluded which 1) did not comment on the cell surface character of mesenchymal stem cells 2) did not involve mesenchymal stem cells 3) identified mesenchymal stem cells in non adults, or embryo 4) were not available for free viewing. A total of 138 articles were reviewed. 29 articles were identified as relevant according to the inclusion criteria. These studies were summarized and the relevant information is presented in Tables 1-5.

## RESULTS

29 studies were identified as relevant according to the inclusion criteria, out of the 138 articles reviewed. Subsequently, these were reviewed carefully and the results summarized in Tables 1 and 2.

As can be seen in Table 1, twenty nine studies looked at mesenchymal cells from different tissues and also identified various cell surface markers characterizing the cells. For easier interpretation, the cell surface markers identified by each study were summarized in Table 2. Gronthos *et al.* [45] stated that adult human bone marrow stromal stem cells (BMSSCs) or mesenchymal stem cells are non-cyclical and express telomerase activity [45]. Tsai *et al.* [19] identified the expression of SH2, SH3, SH4 and HLA-ABC (MHC class I) in addition to CD29, CD44, CD90, CD105. They also found that these multipotent mesenchymal stem cells lack expression of HLA-DR, DP, DQ (MHC class II) and EMA. Another study by Gronthos *et al.* [48] reported that Human adipose tissue-derived stromal cells lack the expression of STRO-1 marker [48]. Positive expression STRO-1 marker was identified by Zuk *et al.* [50], Miura *et al.* [51], Kadar *et al.* [56], Gronthos *et al.* [63], Gronthos *et al.* [64], Stewart *et al.* [65], Simmons *et al.* [66] and Walsh *et al.* [68]. Igura *et al.* [21] found that placenta-derived mesenchymal progenitor cells (PDMPC) express CD105; HLA class I and lack expression of HLA-DR. Zuk *et al.* [50] reported that mesenchymal stem cells were SH2(+), SH3(+). Parte *et al.* [52] found putative stem cells of menopausal human ovarian surface epithelium to be positive for pluripotent gene transcripts Oct-4, Oct-4A, Nanog, Sox-2, TERT, Stat-3. Yu *et al.* [55] reported that there is a low expression of CD45 and CD44 in Adipose-derived

Table 1. Summary of the Relevant Studies

Study	Type of Cell in Study	Cell Surface Character
Dominici <i>et al.</i> [44]	Multipotent mesenchymal stromal cells	These must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules
Gronthos <i>et al.</i> [45]	Adult human bone marrow stromal stem cells	Express telomerase activity <i>in vivo</i>
Ohgushi <i>et al.</i> [46]	Mesenchymal stem cells	Cells were negative for hematopoietic markers (CD14, CD34, CD45) but positive for markers present in mesenchymal cells CD13, CD29, CD90
Wongchuensoontorn <i>et al.</i> [47]	Mesenchymal stem cells	Found a population of CD34 and CD45 negative cells which were positive for CD44, CD73 and CD105
Gronthos <i>et al.</i> [48]	Human adipose tissue-derived stromal cells	CD9, CD10, CD13, CD29, CD34, CD44, CD 49(d), CD 49(e), CD54, CD55, CD59, CD105, CD106, CD146, and CD166. But no STRO-1 antigen was found as in human adipose tissue derived stromal cells
Tsai <i>et al.</i> [19]	Multipotent mesenchymal stem cells	Positive for SH2, SH3, SH4, CD29, CD44 and HLA-ABC (MHC class I), low positive for CD90 and CD105, but negative for CD10, CD11b, CD14, CD34, CD117, HLA-DR, DP, DQ (MHC class II) and EMA
Zvaifler <i>et al.</i> [49]	Mesenchymal precursor cells found in the blood	A minority of adult marrow cells express CD34 BMPCs stained strongly with anti-CD44 antibody. Conventional T-cell (CD3), monocyte (CD14, CD68), and B-cell (CD20) antibodies stained neither of the two BMPC populations, nor did they react to anti-LCA (CD45), anti-VCAM (CD106), or MHC-Class II (anti-DR) [49]
Igura <i>et al.</i> [21]	Placenta-derived mesenchymal progenitor cells (PDMPC)	The PDMPC expressed CD13, CD44, CD73, CD90, CD105 and HLA class I as surface epitopes, but not CD31, CD34, CD45 and HLA-DR.
Zuk <i>et al.</i> [50]	Mesenchymal stem cells	Cells expressed CD29, CD44, CD71, CD90, and CD105/SH2 and SH3, expressed STRO-1. No expression of CD31, CD34, and CD45. Positive expression of CD13 and the absence of CD14, CD16, CD56, CD61, CD62(e), CD104 and CD106. CD49(d) was not observed in MSC culture. However MCS expressed CD106 antigen.
Miura <i>et al.</i> [51]	Stem cells from human exfoliated deciduous teeth (SHED)	SHED were found to express the cell surface molecules STRO-1 and CD146, which are cell surface markings of adult bone marrow-derived stromal stem cells.
Parte <i>et al.</i> [52]	Putative stem cells of menopausal human ovarian surface epithelium	Pluripotent gene transcripts Oct-4, Oct-4A, Nanog, Sox-2, TERT, Stat-3 in human.
Iwata <i>et al.</i> [53]	Human bone marrow-derived mesenchymal stem cells	CD29, CD44, CD90 and CD90
Hasebe <i>et al.</i> [54]	Dermal tissue stem cells	Express CD44, CD54, CD90, CD105 and CD271 which are stem cell markers.
Yu <i>et al.</i> [55]	Adipose-derived stromal/stem cells	CD29(+) CD34(+), CD44(lo) CD45(low) CD73(+) CD90(+) CD105(+)
Kadar <i>et al.</i> [56]	Mesenchymal stem cells	STRO-1 positive
Kyurkchiev <i>et al.</i> [57]	Multipotent endometrial stromal cells and multipotent decidual stromal cells	Express surface molecules CD73, CD90 and CD105
Royer-Pokora <i>et al.</i> [58]	Mesenchymal stem cells	CD105, CD90 and CD73.
Mousavi <i>et al.</i> [59]	Mesenchymal stem cells	Expression of CD105, CD166 and CD44, and the absence of CD45, CD34 and CD14 on the surface of mesenchymal stem cells like cells
Orciani <i>et al.</i> [60]	Mesenchymal stem cells from human skin biopsies (S-MSCs)	Expression of HLA-A, B, C, CD29, CD44, CD73 and CD90, was strongly positive, while CD105 was low positive, and CD10, CD11b, CD14, CD34, CD49d and HLA-DR were negative
Bühring <i>et al.</i> [61]	Mesenchymal stem cells in bone marrow	CD13, CD15, CD73, CD140b, CD144, CD146 and CD164
Latif <i>et al.</i> [62]	Mesenchymal stem cells and human cardiac valve ICs (interstitial cells)	Expressed fibroblast surface antigen, smooth muscle alpha-actin, vimentin and CD44. CD105 was weakly expressed by MSCs (>90%).

(Table 1) contd.....

Study	Type of Cell in Study	Cell Surface Character
Gronthos <i>et al.</i> [63]	Bone marrow derived stromal progenitor cells	STRO-1 positive
Gronthos <i>et al.</i> [64]	Stromal cells derived from the bone marrow	STRO-1 positive
Stewart <i>et al.</i> [65]	Bone marrow-derived mesenchymal stem cells	STRO-1 positive
Simmons and Torok-Storb [66]	BM-derived mesenchymal stem cells STRO-1 positive + CD34 positive	STRO-1 positive, CD34 positive
Simmons <i>et al.</i> [67]	Bone marrow derived mesenchymal stem cells	CD106 positive, CD34 positive
Walsh <i>et al.</i> [68]	Bone marrow-derived mesenchymal stem cells	STRO-1 positive
Conget and Minguell [69]	Human bone marrow mesenchymal progenitor cells	Express integrin subunits alpha4, alpha5, beta1, integrins alphavbeta3 and alphavbeta5, ICAM-1, and CD44H. These were CD49d (-) and CD34 (-).
Pittenger <i>et al.</i> [6]	Adult human mesenchymal stem cells	CD49d (-), CD106 (+), CD34 (-)

stromal/stem cells (ASC). Orciani *et al.* [60] identified the MSCs from human skin biopsies (S-MSCs) to be positive for HLA-A, B, C, and low positive for 105 and negative for HLA-DR. Latif *et al.* [62] reported mesenchymal stem cells to be positive for fibroblast surface antigen, smooth muscle alpha-actin, vimentin and low positive for CD105. Zvaifler *et al.* [49] found that only a minority of bone marrow cells expressed CD34. Conget and Minguell [69] reported the expression of integrin subunits alpha4, alpha5, beta1, integrins alphavbeta3 and alphavbeta5, ICAM-1, and CD44H in human bone marrow mesenchymal progenitor cells.

**DISCUSSION**

In this systematic review we have looked at the cell surface characterization of adult mesenchymal stem cells. We have found that CD105, CD90, CD44, CD73, CD29, CD13, CD34, CD146, CD106, CD54 and CD166 rank among the most commonly reported positive cell surface markers on mesenchymal cells. There are, however, a

number of cell surface markers that have been reported as being absent in mesenchymal stem cells. The most frequently reported are CD34, CD14, CD45, CD11b, CD49d, CD106, CD10 and CD31. In addition to these, a number of other cell surface markers have been identified. These are STRO-1, SH2, SH3, SH4, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-I, DP, EMA, DQ (MHC Class II), CDIO5, Oct 4, Oct 4A, Nanog, Sox-2, TERT, Stat-3, fibroblast surface antigen, smooth muscle alpha-actin, vimentin, integrin subunits alpha4, alpha5, beta1, integrins alphavbeta3 and alphavbeta5 and ICAM-1 [19, 21, 50, 50-52, 56, 60, 62-66, 68, 69]. Eight studies have confirmed the expression of STRO-1 on bone marrow-derived mesenchymal stem cells [50, 51, 56, 63-66, 68]. However, Gronthos *et al.* [48] has reported adipose tissue-derived stromal cells to be STRO-1 negative. This suggests the difference in the expression of STRO-1 depending on whether they are adipose tissue-derived or bone marrow derived; nevertheless it should be noted that these represent only about 3% of the bone marrow stromal population [48, 63-68]. Positive expression of SH2 and SH3 has been

**Table 2. Summary of Positive Cell Surface Markers of Mesenchymal Stem Cells**

Study	CD9	CD10	CD13	CD15	CD29	CD34	CD44	CD44h	CD45	CD49(d)	CD49(e)	CD54	CD55	CD71	CD73	CD90	CD105	CD106	CD140(b)	CD144	CD146	CD164	CD166	CD271
Dominici <i>et al.</i> [44]															CD73	CD90	CD105							
Ohgushi <i>et al.</i> [46]			CD13		CD29											CD90								
Wongchuensoontorn <i>et al.</i> [47]							CD44								CD73		CD105							
Gronthos <i>et al.</i> [48]	CD9	CD10	CD13		CD29	CD34	CD44			CD49(d)	CD49(e)	CD54	CD55				CD105				CD146		CD166	
Tsai <i>et al.</i> [19]					CD29		CD44									CD90	CD105							
Zvaifler <i>et al.</i> [49]						CD34																		
Igura <i>et al.</i> [21]			CD13				CD44								CD73	CD90	CD105							
Zuk <i>et al.</i> [50]			CD13		CD29		CD44							CD71		CD90	CD105							
Miura <i>et al.</i> [51]																					CD146			
Iwata <i>et al.</i> [53]					CD29		CD44									CD90								
Hasebe <i>et al.</i> [54]							CD44					CD54				CD90	CD105							CD271
Yu <i>et al.</i> [55]					CD29	CD34	CD44		CD45						CD73	CD90	CD105							
Kyurkchiev <i>et al.</i> [57]															CD73	CD90	CD105							
Royer-Pokora <i>et al.</i> [58]															CD73	CD90	CD105							
Mousavi <i>et al.</i> [59]							CD44										CD105						CD166	
Orciani <i>et al.</i> [60]					CD29		CD44								CD73	CD90	CD105							
Bähring <i>et al.</i> [61]			CD13	CD15											CD73				CD140(b)	CD144	CD146	CD164		
Latif <i>et al.</i> [62]							CD44																	
Simmons PJ, Torok-Storb B [66]						CD34																		
Simmons <i>et al.</i> [67]						CD34											CD106							
Conget <i>et al.</i> [69]								CD44h																
Pittenger <i>et al.</i> [6]																	CD106							

**Table 3. Summary of Negative Cell Surface Markers and Mesenchymal Stem Cells**

Stud y	CD3	CD10	CD11b	CD14	CD16	CD19	CD31	CD34	CD35	CD36	CD38	CD44	CD45	CD49	CD49d	CD50	CD56	CD61	CD62(E)	CD68	CD79 $\alpha$	CD104	CD106	CD117
Dominici <i>et al.</i> [44]			CD11b	CD14		CD19		CD34					CD45								CD79 $\alpha$			
Ohgushi <i>et al.</i> [46]				CD14				CD34	CD35															
Wongchuensoontorn <i>et al.</i> [47]								CD34					CD45											
Tsai <i>et al.</i> [19]		CD10	CD11b	CD14				CD34																CD117
Zvaifler <i>et al.</i> [49]	CD3			CD14								CD44	CD45							CD68			CD106	
Igura <i>et al.</i> [21]							CD31	CD34					CD45											
Zuk <i>et al.</i> [50]				CD14	CD16		CD31	CD34					CD45		CD49d		CD56	CD61	CD62(E)			CD104	CD106	
Mousavi <i>et al.</i> [59]				CD14				CD34					CD45											
Orciani <i>et al.</i> [60]		CD10	CD11b	CD14				CD34						CD49										
Conget <i>et al.</i> [69]								CD34							CD49d									
Pittnger <i>et al.</i> [6]								CD34							CD49d									

confirmed by Tsai *et al.* [19] and Zuk *et al.* [50]. Igura *et al.* [21] Tsai *et al.* [19] and Orciani *et al.* [60] have all confirmed that mesenchymal stem cells are HLA-DR negative. Orciani *et al.* [60] and Latif *et al.* [62] have both stated that there was low expression of CD105. Another interesting finding in this systematic review is that several studies have reported conflicting findings about the cell surface markings of mesenchymal stem cells. These cells were identified as CD10 (+) by Gronthos *et al.* [45], but as CD10 (-) by Tsai *et al.* [19] and Orciani *et al.* [60]. Similarly Gronthos *et al.* [45], Zvaifler *et al.* [49] and Yu *et al.* [55] identified the cells as CD34 (+) whereas Dominici *et al.* [44], Ohgushi *et al.* [46], Wongchuensoontorn *et al.* [47], Tsai *et al.* [19], Igura *et al.* [21], Zuk *et al.* [50], Mousavi *et al.* [59] and Orciani *et al.* [60] found these to be CD34 (-).

**Table 4. The Mesenchymal Cell Positive Surface Markers and the Number of Studies where they have been Reported**

CD105	12
CD90	11
CD44	11
CD73	8
CD29	7
CD13	5
CD34	5
CD146	3
CD106	2
CD54	2
CD166	2
CD9	1
CD10	1
CD15	1
CD45	1
CD49d	1
CD49e	1
CD55	1
CD71	1
CD140b	1
CD144	1
CD164	1
CD271	1
CD44h	1

**Table 5. The Cell Surface Markers that have been Reported as being Absent on Mesenchymal Stem Cells and the Number of Studies that Reported this**

CD34	10
CD14	7
CD45	6
CD11b	3
CD49d	3
CD106	2
CD10	2
CD31	2
CD62e	1
CD68	1
CD117	1
CD19	1
CD3	1
CD16	1
CD35	1
CD44	1
CD49	1
CD56	1
CD61	1
CD104	1
CD79 $\alpha$	1

In a study to identify the mesenchymal precursor cells in the blood of normal individuals, Zvaifler and colleagues reported on interesting observations. They found that only a minority of these cells express the CD34 surface antigen [49]. They also reported that only 5% of marrow cells reacted with Stro-1 antigen which is one of the defining features of bone marrow MSCs [49, 66]. Moreover, Zvaifler *et al.* stated that the colony forming unit fibroblasts expressed much lower levels of CD34 compared to human hematopoietic stem cells [49]. Other studies have found that CD34 is also expressed on vascular endothelial cells, basement membrane structures, and dendritic and perifollicular cells in human skin [70, 71]. Simmons and Torok-Storb used the expression of CD34 marker to separate human bone marrow cells [72]. As suggested by Zvaifler *et al.* the difference in findings concerning the CD34 antigen could be because all the studies mentioned above were

conducted on MSCs before the culture [49]. The same stromal cells after culture, *in vivo*, do not react with CD34 antibodies anymore [72]. Similarly, despite having been identified in the endothelial cells of human umbilical vein, they have not been found *in vitro* [73]. According to these results we can conclude that the CD34 expression of these cells is highly disputed [74, 75].

CD44 is another cell surface marker that has been identified as positive [19, 21, 45, 47, 50, 53-55, 59, 60, 62] and negative [49]. Yu *et al.* [55] stated that adult mesenchymal stem cells are CD45 positive as opposed to findings by Dominici *et al.* [44], Wongchuensoontorn *et al.* [47], Zvaifler *et al.* [49], Igura *et al.* [21], Zuk *et al.* [50] and Mousavi *et al.* [59] where they have been reported as CD45 negative.

It is important to note that Yu *et al.* [55] reported adult MSCs to express low levels of CD44 and CD45. Gronthos *et al.* [45] found the cells to be CD49d positive, whereas Zuk *et al.* [50] reported them to be CD49d negative. Finally, Simmons *et al.* [67] and Pittenger *et al.* [6] have identified mesenchymal stem cells as CD106 positive but, Zvaifler *et al.* [49] and Zuk *et al.* [50] have found them to be CD106 negative.

A possible explanation for the conflicting results obtained in different papers reviewed is provided in a study conducted by Gronthos and colleagues where gene and protein expression of human adipose tissue-derived stromal cells in their differentiated and undifferentiated states is described. The results obtained were then compared to those of bone marrow stromal cells as previously defined in the literature. As already mentioned in this paper, they found that the expression of surface antigen in adipose tissue-derived stromal cells is not identical to that of bone marrow-derived stromal cells [48]. In this study, two different explanations for the discrepancy in the results have been suggested. Firstly, they argue that these differences may be due to different proliferative stages of the cells in culture [48]. Furthermore, they also state that donor heterogeneity could be of importance when comparing adipose tissue-derived stromal cells with those derived from the bone marrow [48].

In this systematic review we have managed to look at many different studies which discuss the different cell surface markers of adult MSCs. According to the literature reviewed, we can say that there is great discrepancy between the existence and expression of many cell surface markers including CD10, CD34, CD44, CD45, CD49d and CD106, which at times makes it difficult to summarize the available evidence in order to establish a set of clear-cut criteria for identifying these cells. As mentioned earlier, there may be different reasons as to why the expression of these surface markers differs in a number of studies. However, we suggest that further research is needed to identify the cell surface profile of adult MSCs. One possibility would be to choose adult MSCs of the same origin, say bone marrow-derived MSCs, and compare their surface characteristics under the same conditions as other reviews have already provided. Subsequently, the characteristics of a group of cells of the same origin should be assessed under different conditions, such as before and after culture, to observe whether there is any change in the expression of surface markers.

While we hope to have established a good reference for identifying the cell surface markers on adult mesenchymal stem cells, it is important to point out some limitations of this systematic review. 1) The reported cell surface characteristics in the studies reviewed were not all derived from the same tissue. Some were bone marrow-derived [45;50;51;53;56;61;63-66;68], some from skin [54;60] and others from endometrium [57], adipose tissue [48;55], ovaries [52], deciduous teeth [51] and many other sources. 2) Some of the studies included were not specifically aimed at identifying the cell surface markers of adult mesenchymal cells. These studies simply included the surface markings that were identified or compared to other cells. 3) There were fewer studies looking at the negative surface markers of mesenchymal stem cells compared to those identifying the positive cell surface markers. 4) Despite the fact that there are not plenty of studies commenting on identifying adult mesenchymal stem cells, we could argue that the number of studies reviewed is not very large and thus the results need to be interpreted with care.

## CONCLUSION

In this systematic review we have summarized the available research evidence concerning the cell surface profile of adult mesenchymal stem cells. The findings have been presented in Tables 1-5. Different studies have identified various positive and negative surface markers for mesenchymal stem cells. Interestingly, several studies have reported conflicting information about some of the cell surface markers including CD10, CD34, CD44, CD45, CD49d and CD106. We can conclude that the expression of some surface antigens, such as STRO-1, is dependent on whether the cells are adipose tissue-derived or bone marrow-derived. Another factor accounting for the variability in the expression of adult MSC surface markers could be the different stages during cell proliferation and culture where the markers have been accessed. Despite the exhaustive findings of this systematic review, the conflicting evidence and inadequate information about several cell surface markers, we suggest that further research in this field is necessary.

## ACKNOWLEDGEMENT

None declared.

## CONFLICT OF INTEREST

None declared.

## REFERENCES

- [1] Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. *Science* 1997; 276(5309): 71-4.
- [2] Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. 3: 393-403. *Cell Tissue Kinet* 1970; 3: 393-403.
- [3] Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. *Cell Stem Cell* 2008; 2(4): 313-9.
- [4] Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. *J Cell Physiol* 2007; 213(2): 341-7.
- [5] Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. *Arthritis Res Ther* 2007; 9(1): 204.

- [6] Pittenger MF, Mackay AM, Beck SC, *et al.* Multilineage potential of adult human mesenchymal stem cells. *Science* 1999; 284(5411): 143-7.
- [7] Simmons PJ, Przepiora D, Thomas ED, Torok-Storb B. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. *Nature* 1987; 328(6129): 429-32.
- [8] Friedenstein AJ. Stromal mechanisms of bone marrow: cloning *in vitro* and retransplantation *in vivo*. *Haematol Blood Transfus* 1980; 25: 19-29.
- [9] Ratajczak MZ, Zuba-Surma EK, Machalinski B, Kucia M. Bone-marrow-derived stem cells--our key to longevity? *J Appl Genet* 2007; 48(4): 307-19.
- [10] Asahara T, Takahashi T, Masuda H, *et al.* VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. *EMBO J* 1999; 18(14): 3964-72.
- [11] Jiang Y, Jahagirdar BN, Reinhardt RL, *et al.* Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature* 2002; 418(6893): 41-9.
- [12] Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie CM. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. *Blood* 2001; 98(9): 2615-25.
- [13] D'Ippolito G, Diabira S, Howard GA, Menei P, Roos BA, Schiller PC. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. *J Cell Sci* 2004; 117(Pt 14): 2971-81.
- [14] Crisan M, Yap S, Casteilla L, *et al.* A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell* 2008; 3(3): 301-13.
- [15] Rogers I, Casper RF. Umbilical cord blood stem cells. *Best Pract Res Clin Obstet Gynaecol* 2004; 18(6): 893-908.
- [16] Bieback K, Kluter H. Mesenchymal stromal cells from umbilical cord blood. *Curr Stem Cell Res Ther* 2007; 2(4): 310-23.
- [17] Xu Y, Malladi P, Wagner DR, Longaker MT. Adipose-derived mesenchymal cells as a potential cell source for skeletal regeneration. *Curr Opin Mol Ther* 2005; 7(4): 300-5.
- [18] Shi S, Gronthos S. Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. *J Bone Miner Res* 2003; 18(4): 696-704.
- [19] Tsai MS, Lee JL, Chang YJ, Hwang SM. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. *Hum Reprod* 2004; 19(6): 1450-6.
- [20] Bi Y, Ehrichou D, Kilts TM, *et al.* Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. *Nat Med* 2007; 13(10): 1219-27.
- [21] Igura K, Zhang X, Takahashi K, Mitsuru A, Yamaguchi S, Takashi TA. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. *Cytotherapy* 2004; 6(6): 543-53.
- [22] De BC, Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. *Arthritis Rheum* 2001; 44(8): 1928-42.
- [23] Takashima Y, Era T, Nakao K, *et al.* Neuroepithelial cells supply an initial transient wave of MSC differentiation. *Cell* 2007; 129(7): 1377-88.
- [24] Nagoshi N, Shibata S, Kubota Y, *et al.* Ontogeny and multipotency of neural crest-derived stem cells in mouse bone marrow, dorsal root ganglia, and whisker pad. *Cell Stem Cell* 2008; 2(4): 392-403.
- [25] Schipani E, Kronenberg HM. Adult mesenchymal stem cells. *Stembook* 2008; doi: 10.3824/stembook.1.38.1.
- [26] Tsutsumi S, Shimazu A, Miyazaki K, *et al.* Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. *Biochem Biophys Res Commun* 200; 288(2): 413-9.
- [27] Kulterer B, Friedl G, Jandrositz A, *et al.* Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation. *BMC Genomics* 2007; 8: 70.
- [28] Pochampally RR, Smith JR, Ylostalo J, Prockop DJ. Serum deprivation of human marrow stromal cells (hMSCs) selects for a subpopulation of early progenitor cells with enhanced expression of OCT-4 and other embryonic genes. *Blood* 2004; 103(5): 1647-52.
- [29] Hishikawa K, Miura S, Marumo T, *et al.* Gene expression profile of human mesenchymal stem cells during osteogenesis in three-dimensional thermoreversible gelation polymer. *Biochem Biophys Res Commun* 2004; 317(4): 1103-7.
- [30] Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. *Science* 2005; 308(5727): 1472-7.
- [31] Song L, Webb NE, Song Y, Tuan RS. Identification and functional analysis of candidate genes regulating mesenchymal stem cell self-renewal and multipotency. *Stem Cells* 2006; 24(7): 1707-18.
- [32] Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. *Stem Cells* 2007; 25(11): 2896-902.
- [33] Ortiz LA, Dutreil M, Fattman C, *et al.* Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. *Proc Natl Acad Sci USA* 2007; 104(26): 11002-7.
- [34] Kunter U, Rong S, Djuric Z, *et al.* Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. *J Am Soc Nephrol* 2006; 17(8): 2202-12.
- [35] Minguell JJ, Erices A. Mesenchymal stem cells and the treatment of cardiac disease. *Exp Biol Med (Maywood)* 2006; 231(1): 39-49.
- [36] Lee RH, Seo MJ, Reger RL, *et al.* Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. *Proc Natl Acad Sci USA* 2006; 103(46): 17438-43.
- [37] Phinney DG, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. *Curr Pharm Des* 2005; 11(10): 1255-65.
- [38] Prockop DJ. "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). *Clin Pharmacol Ther* 2007; 82(3): 241-3.
- [39] Le BK, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2005; 11(5): 321-34.
- [40] Horwitz EM, Gordon PL, Koo WK, *et al.* Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. *Proc Natl Acad Sci USA* 2002; 99(13): 8932-7.
- [41] Nixon AJ, Goodrich LR, Scimeca MS, Witte TH, Schnabel LV, Watts AE, *et al.* Gene therapy in musculoskeletal repair. *Ann NY Acad Sci* 2007; 1117: 310-27.
- [42] Castro-Malaspina H, Gay RE, Resnick G, *et al.* Characterisation of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. *Blood* 1980; 56: 289-301.
- [43] Civin CI, Trischmann T, Kadan NS, *et al.* Highly purified CD34-positive cells reconstitute hematopoiesis. *J Clin Oncol* 1996; 14(8): 2224-33.
- [44] Dominici M, Le BK, Mueller I, *et al.* Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; 8(4): 315-7.
- [45] Gronthos S, Zannettino AC, Hay SJ, *et al.* Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. *J Cell Sci* 2003; 116(Pt 9): 1827-35.
- [46] Ohgushi H, Kotobuki N, Funaoka H, *et al.* Tissue engineered ceramic artificial joint--ex vivo osteogenic differentiation of patient mesenchymal cells on total ankle joints for treatment of osteoarthritis. *Biomaterials* 2005; 26(22): 4654-61.
- [47] Wongchuensoontorn C, Liebehenschel N, Schwarz U, *et al.* Application of a new chair-side method for the harvest of mesenchymal stem cells in a patient with nonunion of a fracture of the atrophic mandible--a case report. *J Craniomaxillofac Surg* 2009; 37(3): 155-61.
- [48] Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimple JM. Surface protein characterization of human adipose tissue-derived stromal cells. *J Cell Physiol* 2001; 189(1): 54-63.
- [49] Zvaifler NJ, Marinova-Mutafchieva L, Adams G, *et al.* Mesenchymal precursor cells in the blood of normal individuals. *Arthritis Res* 2000; 2(6): 477-88.
- [50] Zuk PA, Zhu M, Ashjian P, *et al.* Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell* 2002; 13(12): 4279-95.
- [51] Miura M, Gronthos S, Zhao M, *et al.* SHED: stem cells from human exfoliated deciduous teeth. *Proc Natl Acad Sci USA* 2003; 100(10): 5807-12.
- [52] Parte SC, Bhartiya D, Telang J, *et al.* Detection, Characterization and Spontaneous Differentiation *in vitro* of Very Small Embryonic-

- like Putative Stem Cells in Adult Mammalian Ovary. *Stem Cells Dev* 2011 [Epub ahead of print].
- [53] Iwata T, Yamato M, Zhang Z, *et al.* Validation of human periodontal ligament-derived cells as a reliable source for cytotherapeutic use. *J Clin Periodontol* 2010; 37(12): 1088-99.
- [54] Hasebe Y, Hasegawa S, Hashimoto N, *et al.* Analysis of cell characterization using cell surface markers in the dermis. *J Dermatol Sci* 2011; 62(2): 98-106.
- [55] Yu G, Wu X, Dietrich MA, *et al.* Yield and characterization of subcutaneous human adipose-derived stem cells by flow cytometric and adipogenic mRNA analyzes. *Cytotherapy* 2010; 12(4): 538-46.
- [56] Kadar K, Kiraly M, Porcsalmy B, *et al.* Differentiation potential of stem cells from human dental origin - promise for tissue engineering. *J Physiol Pharmacol* 2009; 60(Suppl 7): 167-75.
- [57] Kyurkchiev S, Shterev A, Dimitrov R. Assessment of presence and characteristics of multipotent stromal cells in human endometrium and decidua. *Reprod Biomed Online* 2010; 20(3): 305-13.
- [58] Royer-Pokora B, Busch M, Beier M, *et al.* Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm. *Hum Mol Genet* 2010; 19(9): 1651-68.
- [59] Mousavi NN, Jaberipour M, Razmkhah M, Ghaderi A, Habibagahi M. Mesenchymal stem cells do not suppress lymphoblastic leukemic cell line proliferation. *Iran J Immunol* 2009; 6(4): 186-94.
- [60] Orciani M, Mariggio MA, Morabito C, Di BG, Di PR. Functional characterization of calcium-signaling pathways of human skin-derived mesenchymal stem cells. *Skin Pharmacol Physiol* 2010; 23(3): 124-32.
- [61] Buhning HJ, Treml S, Cerabona F, de ZP, Kanz L, Sobiesiak M. Phenotypic characterization of distinct human bone marrow-derived MSC subsets. *Ann N Y Acad Sci* 2009; 1176: 124-34.
- [62] Latif N, Sarathchandra P, Thomas PS, *et al.* Characterization of structural and signaling molecules by human valve interstitial cells and comparison to human mesenchymal stem cells. *J Heart Valve Dis* 2007; 16(1): 56-66.
- [63] Gronthos S, Graves SE, Ohta S, Simmons PJ. The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors. *Blood* 1994; 84(12): 4164-73.
- [64] Gronthos S, Zannettino AC, Graves SE, Ohta S, Hay SJ, Simmons PJ. Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. *J Bone Miner Res* 1999; 14(1): 47-56.
- [65] Stewart K, Walsh S, Screen J, *et al.* Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. *J Bone Miner Res* 1999; 14(8): 1345-56.
- [66] Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. *Blood* 1991; 78(1): 55-62.
- [67] Simmons PJ, Gronthos S, Zannettino A, Ohta S, Graves S. Isolation, characterization and functional activity of human marrow stromal progenitors in hemopoiesis. *Prog Clin Biol Res* 1994; 389: 271-80.
- [68] Walsh S, Jefferiss C, Stewart K, Jordan GR, Screen J, Beresford JN. Expression of the developmental markers STRO-1 and alkaline phosphatase in cultures of human marrow stromal cells: regulation by fibroblast growth factor (FGF)-2 and relationship to the expression of FGF receptors 1-4. *Bone* 2000; 27(2): 185-95.
- [69] Conget PA, Minguell JJ. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. *J Cell Physiol* 1999; 181(1): 67-73.
- [70] Nickoloff BJ. The human progenitor cell antigen (CD34) is localized on endothelial cells, dermal dendritic cells, and perifollicular cells in formalin-fixed normal skin, and on proliferating endothelial cells and stromal spindle-shaped cells in Kaposi's sarcoma. *Arch Dermatol* 1991; 127(4): 523-9.
- [71] Brown J, Greaves MF, Molgaard HV. The gene encoding the stem cell antigen, CD34, is conserved in mouse and expressed in haemopoietic progenitor cell lines, brain, and embryonic fibroblasts. *Int Immunol* 1991; 3(2): 175-84.
- [72] Simmons PJ, Torok-Storb B. CD34 expression by stromal precursors in normal human adult bone marrow. *Blood* 1991; 78(11): 2848-53.
- [73] Fina L, Molgaard HV, Robertson D, *et al.* Expression of the CD34 gene in vascular endothelial cells. *Blood* 1990; 75(12): 2417-26.
- [74] Fernandez M, Simon V, Herrera G, Cao C, Del FH, Minguell JJ. Detection of stromal cells in peripheral blood progenitor cell collections from breast cancer patients. *Bone Marrow Transplant* 1997; 20(4): 265-71.
- [75] Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. *Mol Med* 1994; 1(1): 71-81.

Received: March 3, 2011

Revised: March 24, 2011

Accepted: April 21, 2011

© Mafi *et al.*; Licensee Bentham Open.This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.